Benzinga | Nov 4, 2020 07:33AM EST

Allogene Therapeutics Q3 EPS $(0.52) Beats $(0.54) Estimate

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.54) by 3.7 percent. This is a 4 percent decrease over losses of $(0.50) per share from the same period last year.